#### University of South Florida

## **DIGITAL COMMONS**@ UNIVERSITY OF SOUTH FLORIDA

# Digital Commons @ University of South Florida

Social Work Faculty Publications

Social Work

2023

## Retention and Viral Suppression Among Adolescents Newly Initiating Antiretroviral Therapy in Adult HIV Care in Lima, Peru: A Retrospective Cohort Study

#### Miyu Niwa

Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts

#### Eduardo Matos

Infectious Disease Department, Hospital Nacional Arzobispo Loayza, Lima, Peru

#### Carly Rodriguez

Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts

#### Milagros Wong

Socios En Salud Sucursal Peru, Lima, Peru

#### Renato A. Errea

Socios En Salud Sucursal Peru, Lima, Peru

Follow this and additional works at: https://digitalcommons.usf.edu/sok\_facpub



#### Scholar Commons Citation

Niwa, Miyu; Matos, Eduardo; Rodriguez, Carly; Wong, Milagros; Errea, Renato A.; Ramos, Alicia; Senador, Liz; Contreras, Carmen; Galea, Jerome T.; Lindeborg, Andrew; Benites, Carlos; Shin, Sonya S.; Lecca, Leonid; and Franke, Molly F., "Retention and Viral Suppression Among Adolescents Newly Initiating Antiretroviral Therapy in Adult HIV Care in Lima, Peru: A Retrospective Cohort Study" (2023). *Social Work Faculty Publications*. 227.

https://digitalcommons.usf.edu/sok\_facpub/227

This Article is brought to you for free and open access by the Social Work at Digital Commons @ University of South Florida. It has been accepted for inclusion in Social Work Faculty Publications by an authorized administrator of Digital Commons @ University of South Florida. For more information, please contact digitalcommons@usf.edu.

Authors Miyu Niwa, Edua	rdo Matos, Carly Rodriguez, Milagros Wong, Renato A. Errea, Alicia Ramos, Liz S	enador,
armen Contrera Iolly F. Franke	as, Jerome T. Galea, Andrew Lindeborg, Carlos Benites, Sonya S. Shin, Leonid Leo	cca, and

#### ARTICLE IN PRESS

Journal of Adolescent Health xxx (2023) 1-8



JOURNAL OF
ADOLESCENT
HEALTH

www.jahonline.org

Original article

### Retention and Viral Suppression Among Adolescents Newly Initiating Antiretroviral Therapy in Adult HIV Care in Lima, Peru: A Retrospective Cohort Study

Miyu Niwa, M.S. <sup>a</sup>, Eduardo Matos, M.D. <sup>b</sup>, Carly Rodriguez, Ph.D., M.P.H. <sup>c</sup>, Milagros Wong <sup>d</sup>, Renato A. Errea, M.D., M.M.Sc. <sup>d</sup>, Alicia Ramos, R.N. <sup>d</sup>, Liz Senador, R.N. <sup>d</sup>, Carmen Contreras, M.P.H. <sup>d</sup>, Jerome T. Galea, Ph.D., M.S.W., L.C.S.W. <sup>c,e,f</sup>, Andrew Lindeborg <sup>c</sup>, Carlos Benites, M.D., M.P.H. <sup>g</sup>, Sonya S. Shin, M.D., M.P.H. <sup>h</sup>, Leonid Lecca, M.D., M.Sc. <sup>c,d</sup>, and Molly F. Franke, Sc.D. <sup>c,\*</sup>

Article history: Received December 27, 2022; Accepted August 28, 2023

Keywords: Youth; Adherence; Transition; Support; Peru

ABSTRACT

**Purpose:** Published data on outcomes among adolescents newly initiating antiretroviral treatment in the Latin American context are sparse. We estimated the frequency of sustained retention with viral load suppression (i.e., successful transition) and identified predictors of successful transition into adult care among youth (aged 14–21 years) with recently acquired HIV in Lima Peru

**Methods:** A retrospective cohort study was conducted among 184 adolescents and young adults who initiated antiretroviral therapy in an adult public sector HIV clinic between June 2014 and June 2019. Sustained retention (no loss-to-follow-up or death) with viral suppression was calculated for the first 12 and 24 months following treatment initiation. We conducted regression analyses to assess factors associated with successful transition to adult HIV care, including gender, age, occupation, nationality, pregnancy, same-sex sexual behavior, presence of treatment supporter, number of living parents, and social risk factors that may adversely influence health (e.g., lack of social support, economic deprivation).

**Results:** Patients were predominantly male (n = 167, 90.8%). Median age was 19 years (interquartile range: 18-21). Frequency of sustained retention with viral load suppression was 42.4% (78/184) and 35.3% (30/85) at 12 and 24 months following treatment initiation. In multivariable analyses, working and/or studying was inversely associated with successful transition into adult care at 12 months; number of known living parents (relative risk: 2.20; 95% confidence interval:

## IMPLICATIONS AND CONTRIBUTION

This study identified factors associated with successful transition that may inform future differentiated service interventions to improve outcomes in youth living with behaviorally acquired HIV. The results support the need for deliberate, adolescentfriendly, comprehensive care models to facilitate successful transitions to adult HIV care.

<sup>&</sup>lt;sup>a</sup> Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts

<sup>&</sup>lt;sup>b</sup> Infectious Disease Department, Hospital Nacional Arzobispo Loayza, Lima, Peru

<sup>&</sup>lt;sup>c</sup> Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts

<sup>&</sup>lt;sup>d</sup> Socios En Salud Sucursal Peru, Lima, Peru

<sup>&</sup>lt;sup>e</sup> School of Social Work, University of South Florida, Tampa, Florida

<sup>&</sup>lt;sup>f</sup>College of Public Health, University of South Florida, Tampa, Florida

<sup>&</sup>lt;sup>g</sup> Program for the Control and Prevention of HIV, STDs and Hepatitis, Peru Ministry of Health, Lima, Peru

<sup>&</sup>lt;sup>h</sup> Division of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts

**Conflicts of interest:** The authors have no conflicts of interest to declare.

<sup>\*</sup> Address correspondence to: Molly F. Franke, Sc.D., 641 Huntington Avenue, Boston, MA 02118. E-mail address: molly\_franke@hms.harvard.edu (M.F. Franke).

1.12, 4.34) and absence of social risk factors (relative risk: 1.68; 95% confidence interval: 0.91, 3.11) were positively associated with successful transition at 24 months.

**Discussion:** Sustained retention in HIV care was uncommon. Parental support and interventions targeting social risk factors may contribute to successful transition into adult HIV care in this group.

© 2023 Society for Adolescent Health and Medicine. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

In adolescents and young adults, newly diagnosed HIV may lead to a first experience with routine healthcare. This means that adolescents and young adults who initiate HIV care in an adult clinic will need to navigate the logistics of a complex health system and meet new medical providers in an environment that is unfamiliar, all while simultaneously confronting the emotions of a new HIV diagnosis [1,2]. Adult HIV providers may be unprepared to contend with developmental and behavioral issues of adolescence and young adulthood, including mental health morbidity, disclosure to loved ones, and the potential consequences of sexual debut such as condom negotiation, unprotected sex leading to sexually transmitted infections including HIV, and pregnancy [3]. Furthermore, the adolescent developmental stage is characterized by risk-taking, reward-seeking, and a strong influence from peer networks, all of which may interfere with retention in care and treatment [4,5]. Thus, a complex confluence of factors emerges to challenge adherence, retention, and HIV viral load suppression at a time when adolescents and young adults are expected to assume autonomy in the management of a newly diagnosed condition [6,7].

To date, most HIV care transition studies have focused on adolescents and young adults living with HIV (ALWH) since birth or early childhood who are shifting from a pediatric to adult care provider; however, there is growing recognition that this HIV care transition also applies to those diagnosed with HIV in adolescence or young adulthood, a group that often initiates HIV care directly in an adult clinic [8]. This latter transition experience is particularly relevant in Latin America where most new infections occur between the ages of 18 and 29 years [9]. The health transition experiences and needs of adolescents who transition to adult care from a pediatric clinic and those who initiate HIV care directly in an adult clinic may differ, in part due to the experience of receiving HIV care from a pediatric provider, but also because those who acquire HIV in late adolescence or young adulthood face a distinct set of challenges. For example, in addition to the struggles of newly diagnosed HIV and adjustment to new medications, those diagnosed with HIV during adolescence or young adulthood are more likely to face sexual-based and gender-based stigma, experience substance use disorders, and have a history of trauma and mental health concerns [10-18]. Additionally, while they are more likely to be in the early stages of HIV, and thus less likely to be dealing with long-term or chronic sequelae, they may have difficulties accepting their diagnosis and continue to engage in sexual behaviors that put their partners at risk of HIV [19].

Understanding treatment outcomes among youth who are diagnosed with HIV during adolescence is critical for the design of tailored interventions; however, there are scant data in this group, especially from Latin America. As a first step toward addressing this research gap, we estimated the frequency of sustained retention with viral load suppression among newly

diagnosed ALWH who were initiating treatment in an adult public sector HIV clinic in Lima, Peru, and identified patient-level predictors of a successful transition into adult HIV care.

#### Methods

Study setting

Peru has an estimated 97,000 people living with HIV. Between 2016 and 2020, 28% of new HIV case notifications were between the ages of 15 and 24 years [20]. Our study was conducted in the capital city of Lima, where an estimated 80% of all people living with HIV reside [21,22]. New HIV diagnoses in adolescents between the ages of 15 and 19 years increased by nearly 75% between the periods of 2009-2013 and 2014-2018 [9]. Most new infections in young people occur among men who have sex with men (MSM) and young transgender women, in whom the prevalence exceeds 10% and 20%, respectively [21]. In addition, Peru has welcomed an estimated 1.28 million Venezuelan migrants since 2016, with 80% settling in Lima [23]. This influx has led to an increased representation of Venezuelans living with HIV in Lima. In 2019, the largest HIV program in the country reported that Venezuelans represented 18.7% of new HIV infections [24,25].

In Peru, the transition to an adult HIV clinic typically occurs between the ages of 15 and 18 years; however, newly diagnosed adolescents often enter directly into adult HIV care, bypassing the pediatric clinic. Antiretroviral therapy (ART) has been available free of charge since 2004. During the study period, ART was primarily delivered at public sector tertiary care facilities, and national guidelines specified that patients newly initiating ART should identify a treatment supporter who could offer emotional and adherence support. Viral load and CD4 cell counts were to be measured routinely every six months [26,27], and new patients underwent a psychological evaluation with a Ministry of Health psychologist, at which time a standardized form was completed to record mental health symptomatology and possible diagnoses.

#### Study design and participants

We conducted a retrospective cohort study of adolescents and young adults, aged 14–21 years who initiated ART for the first time in an adult, high-burden public sector HIV clinic hospital in Lima, Peru from June 2014 through February 2019. ALWH were followed from ART initiation until the earliest of death, loss-to-follow-up, March 1, 2020 (start of COVID-19 pandemic), 24 months post-transition or the date of data collection. Each adolescent was eligible to have completed a minimum of 12 months of follow-up. ALWH who disengaged from treatment were retrospectively followed until the time of data collection to determine whether they returned to care.

#### Data collection

Study staff collected patient data from clinical charts including sociodemographic information, HIV viral load and CD4 cell counts, clinic visit attendance, mental health morbidity, living situation, presence of support agent, HIV diagnosis disclosure information, sexual and gender identity, ART regimen, and social factors that may adversely influence health (e.g., substance abuse, economic deprivation, lack of social support, violence, legal problems). These data were abstracted from standardized clinical forms that captured this information and supplemented by health provider notes. To standardize mental health symptomatology and diagnoses, clinical notes were reviewed and doubly coded to the most likely International Classification of Diseases 9 code, by a local Peruvian psychologist and United States-based clinical social worker with more than two decades of experience working in Peru. Initial coding was blinded and discrepancies were resolved through discussion.

#### Outcome measures

The primary outcome was sustained retention in treatment with viral load suppression within 12 and 24 months of ART initiation. Only patients eligible to have completed the full follow-up time were included in each respective analysis. Patients were considered retained with viral suppression ('successful transition') if they were alive and on treatment (i.e., no disengagement from care) for the full duration of follow-up to that point, had at least one suppressed viral load result in the past year, and no unsuppressed viral load result to that point. Disengagement from care was defined as missing ART treatment for at least 60 days and was identified based on clinician report and/or having missed pill-pick-up appointments for at least 60 days. Unsuccessful transition was defined based on disengagement from care, death, or no evidence of a suppressed viral load (i.e., detectable viral load > 40 copies/mL or no viral load testing).

#### Statistical analyses

We report the frequency of primary outcomes and corresponding 95% confidence intervals, using exact methods as needed. We estimated relative risks for potential baseline factors associated with successful transition during the 12-month and 24-month periods using Poisson regression with robust variance. Factors considered included age at transition, gender, calendar year of transition (2014–2016, 2017, 2018, 2019), activity (none, both works and studies, works only, studies only), living alone, presence of treatment supporter, mental health morbidity, number of known living parents, having no social risk factors, sexual identity (MSM or not), nationality (Peruvian or Venezuelan), and baseline CD4 count. If the status of a parent was unknown (i.e., due to estrangement), they were not counted as a known living parent. Factors correlated with successful transition at a *P* value < .20 at either time point (12 or 24 months) were included in the multivariable analyses. We used this liberal threshold because it was likely to capture relevant factors as well as potential confounders of those factors. The small number of patients that transferred out was excluded from regression analyses for the period corresponding to transfer and thereafter. We accounted for the small amount of missing data using the

missing indicator method. All statistical analyses were performed using STATA 16 and SAS version 9.4.

Institutional review board approval/compliance of ethical standards

The authors declare no conflicts of interest. Ethics approval was granted in Peru at Hospital Nacional Arzobispo Loayza and at Harvard Medical School in the United States.

#### Results

#### Cohort characteristics

One hundred eighty four patients eligible to have completed at least 12 months of follow-up at the time of the chart review were included for analysis. Among this study population, 90.8% (n = 167) identified as male (Table 1). The median age at ART initiation was 19 years (25th percentile = 18, 75th percentile = 21) and 16 patients were aged less than 18 years. The median time from diagnosis date to start of ART treatment was 66 days (25th percentile = 33, 75th percentile = 148). Fourteen patients (7.6%) were Venezuelan. Many were students (36.0%), employed (38.2%), or both (11.8%), and a majority reported having a support agent (76.4%). Twenty seven ALWH (14.7%) lived alone.

Frequency of successful transition within 12 and 24 months

We observed a consistent decrease in sustained retention with viral suppression over the course of treatment (Table 2). The frequency of sustained retention with viral load suppression was 42.4% and 35.3% at 12 and 24 months, respectively. Among those who were retained in care, 67.6% (100/148) and 77.8% (42/54) had viral load results at 12 and 24 months, respectively, and of those with viral loads, 78.0% (78/100) and 71.4% (30/42) were suppressed at these time points, respectively. Of 48 ALWH who became lost-to-follow-up, 12 (25%) were observed to have returned to care during the follow-up period.

#### Factors associated with successful transition

Univariable analyses of factors associated with successful transition within 12 and 24 months are shown in Table 3. We found no associations between calendar year and successful transition outcomes. In the multivariable analyses at 12 months, we found inverse associations between successful transition and working (relative risk [RR]: 0.67; 95% confidence interval [CI]: 0.45, 0.99), studying (RR: 0.72; 95% CI: 0.48, 1.07), and both working and studying (RR: 0.44; 95% CI: 0.22, 0.87), relative to neither working nor studying. Having a mental health diagnosis note was positively associated with successful transition at 12 months (RR: 1.39, 95% CI: 1.01, 1.90) (Figure 1, Appendix Table A1). In the multivariable analyses at 24 months, the number of known living parents (0, 1, or 2) (RR: 2.20; 95% CI: 1.12, 4.34) and having no noted social risk factors were positively associated with successful transition (RR: 1.68; 95% CI: 0.91, 3.11; Figure 1, Appendix Table A1).

#### Discussion

Through this retrospective cohort study, we estimated the frequency of retention with viral load suppression, and

**Table 1** Baseline characteristics among newly diagnosed adolescents and young adults living with HIV in urban Peru  $(N=184)^a$ 

Male sex       167 (90.8)         Median age at ART initiation, years (IQR)       19 (18, 21)         Median time from diagnosis to ART transition, days (IQR)       66 (33, 148)         Venezuelan nationality       14 (7.6)         Pregnant at ART initiation, among females (N = 17) <sup>b</sup> 3 (16.7)         MSM, among men (N = 167) <sup>c</sup> 152 (91.0)         Year of ART initiation       1 (0.5)         2014       1 (0.5)         2015       26 (14.1)         2017       20 (34.1)         2018       79 (42.9)         2019       16 (8.7)         Daily Activity (N = 178)       79 (42.9)         2019       25 (14.0)         Both studies and works       21 (11.8)         Only works       68 (38.2)         Only studies       64 (36.0)         Living situation       27 (14.7)         With parent(s)       104 (56.5)         With parent(s)       104 (56.5)         With partner or significant other       19 (10.3)         Has a treatment supporter (N = 178)       139 (76.4)         HIV diagnosis disclosure       9 (4.9)         No one       9 (4.9)         At least one parent       129 (70.1)         Sibling       44 (23.9)<	Characteristic	n (%)
Median age at ART initiation, years (IQR)       19 (18, 21)         Median time from diagnosis to ART transition, days (IQR)       66 (33, 148)         Venezuelan nationality       14 (7.6)         Pregnant at ART initiation, among females (N = 17) <sup>b</sup> 3 (16.7)         MSM, among men (N = 167) <sup>c</sup> 152 (91.0)         Year of ART initiation       1 (0.5)         2015       5 (2.7)         2016       26 (14.1)         2017       57 (31.0)         2018       79 (42.9)         2019       16 (8.7)         Daily Activity (N = 178)       8         None       25 (14.0)         Both studies and works       21 (11.8)         Only works       68 (38.2)         Only studies       64 (36.0)         Living situation       27 (14.7)         With parent(s)       104 (56.5)         With partner or significant other       19 (10.3)         Has a treatment supporter (N = 178)       139 (76.4)         HIV diagnosis disclosure       9 (4.9)         No one       9 (4.9)         At least one parent       129 (70.1)         Sibling       44 (23.9)         Partner       29 (15.8)         Other       40 (21.7)      <	Male sex	167 (90.8)
Median time from diagnosis to ART transition, days (IQR) Venezuelan nationality Pregnant at ART initiation, among females (N = 17) <sup>b</sup> MSM, among men (N = 167) <sup>c</sup> MSM, among men (N = 167) <sup>c</sup> Year of ART initiation  2014  2015  2016  2016  206 (14.1)  2017  2018  2019  2019  16 (8.7)  Daily Activity (N = 178)  None  Both studies and works  Only works  Only studies  Only studies  Only studies  Only studies  With parent(s)  With parent(s)  With parent supporter (N = 178)  HIV diagnosis disclosure  No one  At least one parent  Sibling  Partner  Other  No parent alive, other parent deceased  or status unknown <sup>d</sup> Both parents alive  No social risk factors  Mode of transmission, sexual  Baseline CD4 cell count (N = 178)  TDF, FTC, EFV  Other  TDF, TC, EFV  TDF, FTC, EFV  TOC 101  Siblos  104 (56.5)  104 (56.5)  104 (56.5)  105 (33, 148)  14 (7.6)  15 (16.7)  3 (16.7)  3 (16.7)  3 (16.7)  3 (16.7)  3 (16.7)  3 (16.7)  3 (16.7)  3 (16.7)  3 (16.7)  3 (16.7)  3 (16.7)  3 (16.7)  3 (16.7)  3 (16.7)  3 (16.7)  3 (10.5)  3 (10.5)  3 (10.5)  3 (10.5)  3 (10.5)  3 (10.5)  3 (10.5)  3 (10.5)  3 (10.5)  3 (10.5)  3 (10.5)  3 (10.5)  3 (10.5)  3 (10.5)  3 (10.5)  3 (10.5)  3 (10.5)  3 (10.5)  3 (10.5)  4 (2.7)  Status of parents  Mother and father both dead or status unknown <sup>b</sup> One parent alive, other parent deceased  or status unknown <sup>d</sup> Both parents alive  No social risk factors  Mode of transmission, sexual  Baseline CD4 cell count (N = 178)   12 (60.9)  No social risk factors  29 (15.8)  Mode of transmission, sexual  Baseline CD4 cell count (N = 178)   5 (2.8)	Median age at ART initiation, years (IOR)	
Venezuelan nationality Pregnant at ART initiation, among females (N = 17) <sup>b</sup> RSM, among men (N = 167) <sup>c</sup> Year of ART initiation  2014  2015  2016  2017  2016  2017  2018  2019  2019  2019  106 (8.7)  Daily Activity (N = 178)  None  Both studies and works  Only works  Only studies  Living situation  Alone  Alone  With parent(s)  With other family member(s), but not with parent  With parent or significant other  No one  At least one parent  Sibling  Partner  Other  Status of parents  Mother and father both dead or status unknown <sup>b</sup> One parent alive, other parent deceased  or status unknown <sup>d</sup> Both parents alive  No one parent alive, other parent deceased  or status unknown <sup>d</sup> Both parents alive  No social risk factors  Mode of transmission, sexual  Baseline CD4 cell count (N = 178)  TDF, FTC, EFV  Other  TDF, STC, EFV  FTC, EFV  Other  10 (50.5)  15 (2.7)  15 (10.5)  26 (14.1) 26 (14.1) 27 (14.7) 26 (14.1) 26 (14.1) 27 (14.7) 28 (15.2) 29 (15.8) 30 (16.3) 30		
MSM, among men (N = 167) <sup>c</sup> Year of ART initiation  2014 2015 2015 2016 26 (14.1) 2017 2018 2019 2019 2019 2019 3016 (8.7)  Both studies and works Only works Only studies Living situation Alone With parent(s) With other family member(s), but not with parent With partner or significant other HIV diagnosis disclosure No one No one At least one parent Sibling Partner Other Status of parents Mother and father both dead or status unknown <sup>b</sup> One parent alive, other parent deceased or status unknown <sup>d</sup> Both parents alive No social risk factors Mode of transmission, sexual Baseline CD4 cell count (N = 178) Status of parent TDF, 3TC, EFV TDF, FTC, EFV TOTH TISH TOTH TOTH TOTH TOTH TOTH TOTH TOTH TO	Venezuelan nationality	14 (7.6)
MSM, among men (N = 167) <sup>c</sup> Year of ART initiation  2014 2015 2015 2016 26 (14.1) 2017 2018 2019 2019 2019 3019 3019 3019 3010 3019 3019 3019 3	Pregnant at ART initiation, among females (N = 17) <sup>b</sup>	3 (16.7)
2014 1 (0.5) 2015 5 (2.7) 2016 26 (14.1) 2017 57 (31.0) 2018 79 (42.9) 2019 16 (8.7)  Daily Activity (N = 178)  None 25 (14.0)  Both studies and works 21 (11.8) Only works 68 (38.2) Only studies 1.2 (11.8) Only studies 64 (36.0)  Living situation Alone 27 (14.7) With parent(s) 104 (56.5) With other family member(s), but not with parent 28 (15.2) With partner or significant other 19 (10.3) Has a treatment supporter (N = 178) 139 (76.4) HIV diagnosis disclosure No one 9 (4.9) At least one parent 129 (70.1) Sibling 44 (23.9) Partner 29 (15.8) Other 30 (16.3) One parent alive, other parent deceased 40 (21.7) Status of parents Mother and father both dead or status unknown 50 or status unknown 61 (12.6) One parent alive, other parent deceased 42 (22.8) Or status unknown 61 (12.6) Both parents alive 112 (60.9) No social risk factors 29 (15.8) Mode of transmission, sexual Baseline CD4 cell count (N = 178) < 50 5 (2.8) 51-200 20 (11.2) 201-500 95 (53.4) > 500 Antiretroviral regimen TDF, 3TC, EFV 66 (35.9) TDF, FTC, EFV 101 (54.9) Other 17 (10.2)	MSM, among men $(N = 167)^{c}$	
2015 5 (2.7) 2016 26 (14.1) 2017 57 (31.0) 2018 79 (42.9) 2019 16 (8.7)  Daily Activity (N = 178)  None 25 (14.0) Both studies and works 21 (11.8) Only works 68 (38.2) Only studies (4 (36.0)  Living situation  Alone 27 (14.7) With parent(s) 104 (56.5) With other family member(s), but not with parent 28 (15.2) With partner or significant other 19 (10.3) Has a treatment supporter (N = 178) 139 (76.4) HIV diagnosis disclosure No one 9 (4.9) At least one parent 129 (70.1) Sibling 44 (23.9) Partner 29 (15.8) Other 30 (16.3) One parent alive, other parent deceased 42 (22.8) or status unknownd Both parents alive 112 (60.9) No social risk factors 29 (15.8) Mode of transmission, sexual Baseline CD4 cell count (N = 178)  S (2.8) 51−200 20 (11.2) 201−500 95 (53.4) > 500 Antiretroviral regimen  TDF, 3TC, EFV 66 (35.9) TDF, FTC, EFV 101 (54.9) Other 17 (10.2)	Year of ART initiation	
2016 26 (14.1) 2017 57 (31.0) 2018 79 (42.9) 2019 16 (8.7)  Daily Activity (N = 178)  None 25 (14.0)  Both studies and works 21 (11.8) Only works 68 (38.2) Only studies (4 (36.0)  Living situation  Alone 27 (14.7) With parent(s) 104 (56.5) With other family member(s), but not with parent 28 (15.2) With partner or significant other 19 (10.3) Has a treatment supporter (N = 178) 139 (76.4) HIV diagnosis disclosure  No one 9 (4.9) At least one parent 129 (70.1) Sibling 44 (23.9) Partner 29 (15.8) Other 29 (15.8) Other 40 (21.7) Status of parents  Mother and father both dead or status unknown 40 Both parent alive, other parent deceased 42 (22.8) or status unknown 4 Both parents alive 112 (60.9) No social risk factors 29 (15.8) Mode of transmission, sexual Baseline CD4 cell count (N = 178) < 50 51-200 20 (11.2) 201-500 95 (53.4) > 500 Antiretroviral regimen  TDF, 3TC, EFV 66 (35.9) TDF, FTC, EFV 101 (54.9) Other 17 (10.2)	2014	1 (0.5)
2017       57 (31.0)         2018       79 (42.9)         2019       16 (8.7)         Daily Activity (N = 178)       16 (8.7)         None       25 (14.0)         Both studies and works       21 (11.8)         Only works       68 (38.2)         Only studies       64 (36.0)         Living situation       27 (14.7)         Alone       27 (14.7)         With parent(s)       104 (56.5)         With other family member(s), but not with parent       28 (15.2)         With partner or significant other       19 (10.3)         Has a treatment supporter (N = 178)       139 (76.4)         HIV diagnosis disclosure       9 (4.9)         No one       9 (4.9)         At least one parent       129 (70.1)         Sibling       44 (23.9)         Partner       29 (15.8)         Other       40 (21.7)         Status of parents       Mother and father both dead or status unknownb       30 (16.3)         One parent alive, other parent deceased       42 (22.8)         or status unknownd       112 (60.9)         No social risk factors       29 (15.8)         Mode of transmission, sexual       184 (100.0)         Baseline CD4 cell count (N	2015	5 (2.7)
2018       79 (42.9)         2019       16 (8.7)         Daily Activity (N = 178)       16 (8.7)         None       25 (14.0)         Both studies and works       21 (11.8)         Only works       68 (38.2)         Only studies       64 (36.0)         Living situation       27 (14.7)         With parent(s)       104 (56.5)         With other family member(s), but not with parent       28 (15.2)         With partner or significant other       19 (10.3)         Has a treatment supporter (N = 178)       139 (76.4)         HIV diagnosis disclosure       9 (4.9)         No one       9 (4.9)         At least one parent       129 (70.1)         Sibling       44 (23.9)         Partner       29 (15.8)         Other       40 (21.7)         Status of parents       30 (16.3)         Mother and father both dead or status unknown <sup>b</sup> 30 (16.3)         One parent alive, other parent deceased       42 (22.8)         or status unknown <sup>d</sup> 112 (60.9)         No social risk factors       29 (15.8)         Mode of transmission, sexual       184 (100.0)         Baseline CD4 cell count (N = 178)       5 (2.8)         51–200	2016	26 (14.1)
Daily Activity (N = 178)  None  Both studies and works Only works Only studies Living situation Alone Alone With parent(s) With other family member(s), but not with parent With partner or significant other HIV diagnosis disclosure No one At least one parent Sibling Partner Other Status of parents Mother and father both dead or status unknown One parent alive, other parent deceased or status unknownd Both parents alive No social risk factors Mode of transmission, sexual Baseline CD4 cell count (N = 178) Status of parent  None Solo 5 (2.8) S1−200 S1−200 S2 (11.2) S2 (25,9) Cher TDF, 3TC, EFV TDF, FTC, EFV TOTHER TIVING TO THE TIVING	2017	57 (31.0)
Daily Activity (N = 178)       25 (14.0)         None       25 (14.0)         Both studies and works       21 (11.8)         Only works       68 (38.2)         Only studies       64 (36.0)         Living situation       27 (14.7)         Alone       27 (14.7)         With parent(s)       104 (56.5)         With other family member(s), but not with parent       28 (15.2)         With partner or significant other       19 (10.3)         Has a treatment supporter (N = 178)       139 (76.4)         HIV diagnosis disclosure       30 (9.9)         No one       9 (4.9)         At least one parent       129 (70.1)         Sibling       44 (23.9)         Partner       29 (15.8)         Other       40 (21.7)         Status of parents       Mother and father both dead or status unknown <sup>b</sup> 30 (16.3)         One parent alive, other parent deceased       42 (22.8)         or status unknown <sup>d</sup> 112 (60.9)         No social risk factors       29 (15.8)         Mode of transmission, sexual       184 (100.0)         Baseline CD4 cell count (N = 178)       5 (2.8)         < 50	2018	79 (42.9)
None Both studies and works Only works Only works Only studies Living situation Alone Alo		16 (8.7)
Both studies and works Only works Only studies Only studies Living situation Alone Alone With parent(s) With partner or significant other HIV diagnosis disclosure No one At least one parent Sibling Partner Other Status of parents Mother and father both dead or status unknownb One parent alive, other parent deceased or status unknownd Both parents alive No social risk factors Mode of transmission, sexual Baseline CD4 cell count (N = 178) Solution Sol	Daily Activity $(N = 178)$	
Only works Only studies Living situation Alone Alone With parent(s) With parent(s), but not with parent With partner or significant other With diagnosis disclosure No one  9 (4.9) At least one parent Sibling 44 (23.9) Partner Other Wother and father both dead or status unknown Other and father both dead or status unknown One parent alive, other parent deceased or status unknown Both parents alive No social risk factors Mode of transmission, sexual Baseline CD4 cell count (N = 178) < 50 51–200 20 (11.2) 201–500 > 500 58 (32.6) Antiretroviral regimen TDF, 3TC, EFV TDF, FTC, EFV TOTH, TC, EFV		
Only studies       64 (36.0)         Living situation       27 (14.7)         Alone       27 (14.7)         With parent(s)       104 (56.5)         With other family member(s), but not with parent       28 (15.2)         With partner or significant other       19 (10.3)         Has a treatment supporter (N = 178)       139 (76.4)         HIV diagnosis disclosure       9 (4.9)         No one       9 (4.9)         At least one parent       129 (70.1)         Sibling       44 (23.9)         Partner       29 (15.8)         Other       40 (21.7)         Status of parents       30 (16.3)         Mother and father both dead or status unknownb       30 (16.3)         One parent alive, other parent deceased       42 (22.8)         or status unknownd       112 (60.9)         No social risk factors       29 (15.8)         Mode of transmission, sexual       184 (100.0)         Baseline CD4 cell count (N = 178)       5 (2.8)         51–200       20 (11.2)         201–500       5 (3.4)         > 500       58 (32.6)         Antiretroviral regimen       TDF, 3TC, EFV       66 (35.9)         TDF, TTC, EFV       101 (54.9)		
Living situation  Alone  Alone  Alone  Alone  Alone  Alone  Alone  Alone  With parent(s)  With other family member(s), but not with parent  28 (15.2)  With partner or significant other  Has a treatment supporter (N = 178)  HIV diagnosis disclosure  No one  At least one parent  Sibling  At (23.9)  Partner  Other  Other  Mother and father both dead or status unknown  One parent alive, other parent deceased  or status unknown  Both parents alive  No social risk factors  Mode of transmission, sexual  Baseline CD4 cell count (N = 178)  < 50  5 (2.8)  51–200  20 (11.2)  201–500  5 (3.4)  > 500  Antiretroviral regimen  TDF, 3TC, EFV  TOF, FTC, EFV  Other  17 (10.2)		
Alone Alone With parent(s) With parent(s) With other family member(s), but not with parent With parent or significant other With partner or significant other Has a treatment supporter (N = 178) Has a treatment supporter (N = 178) HIV diagnosis disclosure No one At least one parent Sibling Partner Part		64 (36.0)
With parent(s) 104 (56.5) With other family member(s), but not with parent 28 (15.2) With partner or significant other 19 (10.3) Has a treatment supporter (N = 178) 139 (76.4) HIV diagnosis disclosure No one 9 (4.9) At least one parent 129 (70.1) Sibling 44 (23.9) Partner 29 (15.8) Other 29 (15.8) Other 40 (21.7) Status of parents Mother and father both dead or status unknown 30 (16.3) One parent alive, other parent deceased 42 (22.8) or status unknown 4 Both parents alive 112 (60.9) No social risk factors 29 (15.8) Mode of transmission, sexual Baseline CD4 cell count (N = 178) < 50 5 (2.8) 51–200 20 (11.2) 201–500 95 (53.4) > 500 58 (32.6) Antiretroviral regimen TDF, 3TC, EFV 66 (35.9) TDF, FTC, EFV 101 (54.9) Other 17 (10.2)	e e e e e e e e e e e e e e e e e e e	
With other family member(s), but not with parent       28 (15.2)         With partner or significant other       19 (10.3)         Has a treatment supporter (N = 178)       139 (76.4)         HIV diagnosis disclosure       9 (4.9)         No one       9 (4.9)         At least one parent       129 (70.1)         Sibling       44 (23.9)         Partner       29 (15.8)         Other       40 (21.7)         Status of parents       Mother and father both dead or status unknown¹b       30 (16.3)         One parent alive, other parent deceased       42 (22.8)         or status unknown⁴       112 (60.9)         No social risk factors       29 (15.8)         Mode of transmission, sexual       184 (100.0)         Baseline CD4 cell count (N = 178)       5 (2.8)         ≤ 50       5 (2.8)         51−200       20 (11.2)         201−500       95 (53.4)         > 500       58 (32.6)         Antiretroviral regimen       TDF, 3TC, EFV       66 (35.9)         TDF, TTC, EFV       101 (54.9)         Other       17 (10.2)	1	, ,
With partner or significant other       19 (10.3)         Has a treatment supporter (N = 178)       139 (76.4)         HIV diagnosis disclosure       9 (4.9)         No one       9 (4.9)         At least one parent       129 (70.1)         Sibling       44 (23.9)         Partner       29 (15.8)         Other       40 (21.7)         Status of parents       30 (16.3)         Mother and father both dead or status unknownb       30 (16.3)         One parent alive, other parent deceased       42 (22.8)         or status unknownd       112 (60.9)         No social risk factors       29 (15.8)         Mode of transmission, sexual       184 (100.0)         Baseline CD4 cell count (N = 178)       50         < 50		
Has a treatment supporter (N = 178)  HIV diagnosis disclosure  No one  At least one parent  Sibling  Partner  Other  Status of parents  Mother and father both dead or status unknown  One parent alive, other parent deceased  or status unknownd  Both parents alive  No social risk factors  Mode of transmission, sexual  Baseline CD4 cell count (N = 178)  < 50  51–200  20 (11.2)  201–500  > 50  Antiretroviral regimen  TDF, 3TC, EFV  TDF, FTC, EFV  Other  112 (60.9)  139 (76.4)  149 (2.9)  9 (4.9)  9 (4.9)  9 (4.9)  9 (4.9)  9 (4.9)  9 (4.9)  9 (4.9)  9 (4.9)  10 (6.9)  No (2.1)  9 (15.8)  10 (6.3)  9 (16.3)  9 (16.3)  10 (6.3)  10 (6.3)  9 (16.3)  10 (6.3)  10 (6.3)  9 (1.3)  10 (54.9)  10 (54.9)  Other		, ,
HIV diagnosis disclosure  No one At least one parent At least one parent Sibling Partner Other Sibling At (23.9) Partner 29 (15.8) Other At least one parent Other At (21.7) Status of parents Mother and father both dead or status unknown One parent alive, other parent deceased or status unknown Both parents alive At (22.8) No social risk factors And of transmission, sexual Baseline CD4 cell count (N = 178)  < 50 51–200 20 (11.2) 201–500 95 (53.4) > 500 Antiretroviral regimen TDF, 3TC, EFV Affice TDF, 3TC, EFV TOF, FTC, EFV Other T129 (5.9) T129 (7.01) 129 (1.29) 129 (15.8) At least one parent 129 (70.1) 129 (129.8) 129 (15.8) 129 (15.8) 129 (15.8) 120 (11.2) 120 (		, ,
No one At least one parent At least one parent Sibling Partner Other Other At least one parent Sibling Partner 29 (15.8) Other At (21.7) Status of parents Mother and father both dead or status unknown One parent alive, other parent deceased or status unknown Both parents alive No social risk factors Mode of transmission, sexual Baseline CD4 cell count (N = 178) < 50 51–200 20 (11.2) 201–500 5 (2.8) 51–200 5 (3.4) > 500 Antiretroviral regimen TDF, 3TC, EFV TOF, FTC, EFV TOF, FTC, EFV Other 17 (10.2)		139 (76.4)
At least one parent 129 (70.1)  Sibling 44 (23.9)  Partner 29 (15.8)  Other 40 (21.7)  Status of parents  Mother and father both dead or status unknown 30 (16.3)  One parent alive, other parent deceased 42 (22.8)  or status unknown 4  Both parents alive 112 (60.9)  No social risk factors 29 (15.8)  Mode of transmission, sexual 184 (100.0)  Baseline CD4 cell count (N = 178)  < 50 51-200 20 (11.2)  201-500 95 (53.4)  > 500 58 (32.6)  Antiretroviral regimen  TDF, 3TC, EFV 66 (35.9)  TDF, FTC, EFV 101 (54.9)  Other 17 (10.2)		0 (40)
Sibling       44 (23.9)         Partner       29 (15.8)         Other       40 (21.7)         Status of parents       40 (21.7)         Mother and father both dead or status unknown <sup>b</sup> 30 (16.3)         One parent alive, other parent deceased       42 (22.8)         or status unknown <sup>d</sup> 112 (60.9)         No social risk factors       29 (15.8)         Mode of transmission, sexual       184 (100.0)         Baseline CD4 cell count (N = 178)       5 (2.8)         51-200       20 (11.2)         201-500       95 (53.4)         > 500       58 (32.6)         Antiretroviral regimen       TDF, 3TC, EFV         TDF, TTC, EFV       101 (54.9)         Other       17 (10.2)		, ,
Partner         29 (15.8)           Other         40 (21.7)           Status of parents         30 (16.3)           Mother and father both dead or status unknown <sup>b</sup> 30 (16.3)           One parent alive, other parent deceased or status unknown <sup>d</sup> 42 (22.8)           Both parents alive         112 (60.9)           No social risk factors         29 (15.8)           Mode of transmission, sexual         184 (100.0)           Baseline CD4 cell count (N = 178)         5 (2.8)           51-200         20 (11.2)           201-500         95 (53.4)           > 500         58 (32.6)           Antiretroviral regimen         TDF, 3TC, EFV           TDF, 3TC, EFV         66 (35.9)           TDF, FTC, EFV         101 (54.9)           Other         17 (10.2)		
Other       40 (21.7)         Status of parents       40 (21.7)         Mother and father both dead or status unknown <sup>b</sup> 30 (16.3)         One parent alive, other parent deceased       42 (22.8)         or status unknown <sup>d</sup> 112 (60.9)         No social risk factors       29 (15.8)         Mode of transmission, sexual       184 (100.0)         Baseline CD4 cell count (N = 178)       5 (2.8)         51-200       20 (11.2)         201-500       95 (53.4)         > 500       58 (32.6)         Antiretroviral regimen       TDF, 3TC, EFV       66 (35.9)         TDF, FTC, EFV       101 (54.9)         Other       17 (10.2)	· ·	
Status of parents  Mother and father both dead or status unknown <sup>b</sup> One parent alive, other parent deceased or status unknown <sup>d</sup> Both parents alive  No social risk factors  Mode of transmission, sexual Baseline CD4 cell count (N = 178)  < 50 51–200 20 (11.2) 201–500 95 (53.4) > 500 Antiretroviral regimen  TDF, 3TC, EFV TDF, FTC, EFV Other  17 (10.2)		, ,
Mother and father both dead or status unknown <sup>b</sup> 30 (16.3)         One parent alive, other parent deceased or status unknown <sup>d</sup> 42 (22.8)         or status unknown <sup>d</sup> 112 (60.9)         Both parents alive       112 (60.9)         No social risk factors       29 (15.8)         Mode of transmission, sexual       184 (100.0)         Baseline CD4 cell count (N = 178)       5 (2.8)         51-200       20 (11.2)         201-500       95 (53.4)         > 500       58 (32.6)         Antiretroviral regimen       TDF, 3TC, EFV       66 (35.9)         TDF, TFC, EFV       101 (54.9)         Other       17 (10.2)		40 (21.7)
One parent alive, other parent deceased or status unknown <sup>d</sup> Both parents alive 112 (60.9)  No social risk factors 29 (15.8)  Mode of transmission, sexual 184 (100.0)  Baseline CD4 cell count (N = 178)  < 50 5 (2.8)  51–200 20 (11.2)  201–500 95 (53.4)  > 500 58 (32.6)  Antiretroviral regimen  TDF, 3TC, EFV 66 (35.9)  TDF, FTC, EFV 101 (54.9)  Other 17 (10.2)	*	30 (163)
or status unknown <sup>d</sup> Both parents alive 112 (60.9)  No social risk factors 29 (15.8)  Mode of transmission, sexual 184 (100.0)  Baseline CD4 cell count (N = 178)  < 50 5 (2.8)  51–200 20 (11.2)  201–500 95 (53.4)  > 500 58 (32.6)  Antiretroviral regimen  TDF, 3TC, EFV 66 (35.9)  TDF, FTC, EFV 101 (54.9)  Other 17 (10.2)		, ,
Both parents alive 112 (60.9)  No social risk factors 29 (15.8)  Mode of transmission, sexual 184 (100.0)  Baseline CD4 cell count (N = 178)  < 50 5 (2.8)  51−200 20 (11.2)  201−500 95 (53.4)  > 500 58 (32.6)  Antiretroviral regimen  TDF, 3TC, EFV 66 (35.9)  TDF, FTC, EFV 101 (54.9)  Other 17 (10.2)		12 (22.0)
No social risk factors 29 (15.8)  Mode of transmission, sexual 184 (100.0)  Baseline CD4 cell count (N = 178)  < 50 5 (2.8)  51-200 20 (11.2)  201-500 95 (53.4)  > 500 58 (32.6)  Antiretroviral regimen  TDF, 3TC, EFV 66 (35.9)  TDF, FTC, EFV 101 (54.9) Other 17 (10.2)		112 (60.9)
Mode of transmission, sexual     184 (100.0)       Baseline CD4 cell count (N = 178)     5 (2.8)       51-200     20 (11.2)       201-500     95 (53.4)       > 500     58 (32.6)       Antiretroviral regimen     TDF, 3TC, EFV     66 (35.9)       TDF, FTC, EFV     101 (54.9)       Other     17 (10.2)	•	, ,
Baseline CD4 cell count (N = 178)  < 50		
< 50	·	, , , , ,
51-200       20 (11.2)         201-500       95 (53.4)         > 500       58 (32.6)         Antiretroviral regimen       TDF, 3TC, EFV       66 (35.9)         TDF, FTC, EFV       101 (54.9)         Other       17 (10.2)		5 (2.8)
> 500 58 (32.6)  Antiretroviral regimen  TDF, 3TC, EFV 66 (35.9)  TDF, FTC, EFV 101 (54.9)  Other 17 (10.2)	51-200	
Antiretroviral regimen  TDF, 3TC, EFV  66 (35.9)  TDF, FTC, EFV  101 (54.9)  Other  17 (10.2)	201-500	95 (53.4)
TDF, 3TC, EFV 66 (35.9) TDF, FTC, EFV 101 (54.9) Other 17 (10.2)	> 500	58 (32.6)
TDF, FTC, EFV 101 (54.9) Other 17 (10.2)	Antiretroviral regimen	
Other 17 (10.2)		66 (35.9)
· · · · · · · · · · · · · · · · · · ·	TDF, FTC, EFV	101 (54.9)
Possible mental health diagnosis <sup>e</sup> 46 (25.0)	Other	17 (10.2)
	Possible mental health diagnosis <sup>e</sup>	46 (25.0)

ART = antiretroviral therapy; CD4 = clusters of differentiation 4; HIV = human immunodeficiency virus; IQR = interquartile range; MSM = men who have sex with men; TDF, 3TC, EFV = tenofovir, lamivudine, efavirenz; TDF, FTC, EFV = tenofivir, emtricitabine, efavirenz.

- $^{a}$  N = 184 unless specified otherwise.
- <sup>b</sup> Pregnant women represented 1.6% of the entire cohort of 184.
- <sup>c</sup> MSM represented 82.6% of the entire cohort of 184.
- <sup>d</sup> Unknown status of mother only: 0, Unknown status of father only: 42, Unknown status of both: 29.
- $^{\rm e}$  Reviewers arrived at this diagnostic code based on available data; however, insufficient data were available (e.g., duration of symptoms) to make a definitive diagnostic code assignment. Possible mental health diagnoses included adjustment disorders (n = 7), schizophrenia (n = 1), depressive disorders (n = 5 diagnosed, n = 31 probable), anxiety disorders (n = 3), mixed receptive-expressive language disorder (n = 1), and oppositional defiant disorder (n = 1).

associated factors, among adolescents and young adults newly initiating ART at a public sector adult HIV clinic in urban Peru. We saw consistent declines in the frequency of sustained retention with viral load suppression during the two years of treatment. Among those that were retained, lack of a viral load test result

and lack of viral suppression were common. The "95–95–95" global target to end the AIDS epidemic aims to have 95% of those living with HIV be diagnosed, 95% of those diagnosed be receiving treatment, and 95% of those with treatment having suppressed viral loads by 2030 [28]. Studies have revealed gaps in this HIV cascade among younger individuals who have transitioned to adult care, to which our results, and others from Peru, are consistent, highlighting the critical need for tailored interventions for this group [13,17,29–33].

Barriers to successful linkage to care among newly diagnosed ALWH include providers' failure to address adolescent concerns, as well as the difference in care cultures between the HIV clinics [34]. Negative perceptions or concerns about adult HIV clinics have also been identified as challenges to transition [17]. In our study, no single risk factor predicted successful transition across the two follow-up periods; however, having known living parents and having no social risk factors for unfavorable health outcomes facilitated sustained retention with viral load suppression for the first two years of treatment, highlighting the critical importance of differentiated service interventions that provide more intensive and/or comprehensive support for some ALWH. We also found that the frequency of successful transition was lower in the year following ART initiation for those who reported working, studying, or both working and studying, relative to those who did neither. In Peru, patients often receive ART in centralized tertiary care centers that may be far from home and typically operate during daytime business hours. Thus, patients may need to take time off of work or school to refill medications. In addition, a possible mental health diagnosis in the clinical record was associated with a successful outcome in the first year since ART initiation, a finding at odds with a large body of evidence demonstrating the deleterious effects of mental health morbidity on HIV-related outcomes [35-39]. Most of those with a mental health diagnosis had a 'possible,' unconfirmed, diagnosis, thus the data may not be fully reliable. In addition, while all patients were evaluated by a psychologist, in the absence of systematic screening for mental health morbidity, it is possible that some existing mental health conditions were missed. While this result may be a chance finding, those with early mental health diagnoses may be given more attention by providers early on in care or be more likely to be engaged in mental health service utilization; the latter has been associated with retention in care [35]. This finding could be explored more fully in a prospective study in which data on symptomatology, diagnoses, communication of diagnoses to the adolescent, and any subsequent treatment are systematically captured.

Our findings highlight the need for interventions to support for ALWH who are newly initiating ART and provide strong motivation for further exploration into the transition experiences among newly diagnosed ALWH in Peru with the goal of ensuring a comprehensive, coordinated, and compassionate model of care during the transition to HIV treatment and beyond. Directly addressing adolescent-specific needs has been associated with successful treatment adherence in the past [40-43]. There is increasing recognition of the importance of active engagement by adult HIV care clinics during the transition process to increase coordination and support for adolescents during this critical step in the continuum of care [44]. A study among adolescents in Uganda found that having trusting peer educators for treatment, receiving counseling on the transition to adult services, and visiting an adult clinic to prepare for transition were associated with perceived readiness to transition into adult care [45]. While

 Table 2

 Frequency of treatment retention and successful viral load suppression at 12 and 24 months among adolescents and young adults with recently diagnosed HIV in Lima, Peru

Time	N at risk*	Outcomes n (%, 95% CI)						
		Retained with VL suppression	Retained with no VL data	Retained with detectable VL	Not retained	Transferred out		
12 months 24 months	184 85	78 (42.4, 35.4–49.7) 30 (35.3, 25.8–46.1)	48 (26.1, 20.2–33.0) 12 (14.1, 8.1–23.4)	22 (12.0, 8.0–17.5) 12 (14.1, 8.1–23.4)	29 (15.8, 11.2–21.8) 29 (34.12, 24.7–44.9)	7 (3.80, 1.8–7.8) 2 (2.4, 0.6–9.1)		

CI = confidence interval: VL = viral load.

these results were from patients who transitioned from pediatric clinics, improving readiness to transition may be critical among newly diagnosed ALWH who transition directly into adult care as well. In their pilot program optimizing linkage to care in Kenya, Ruria et al. found that active youth engagement and youthfriendly programming for newly diagnosed adolescents and youth were associated with increased retention in care [42]. In Peru, a single-arm pilot study of a community-based differentiated care intervention that aimed to fill gaps in care, provide social and logistical support, and build skills during the transition process saw improvements in social support, adherence, and transition readiness, among adolescents with perinatal and recent HIV infection alike [41,46]. While there are increasing studies exploring adolescents' transition experiences and treatment adherence and outcomes, there remains an evidence gap with regard to experiences of adolescents and young adults newly diagnosed with HIV who are engaging in adult care for the first time, particularly in Peru and Latin America.

We did not identify a set of factors that were consistently associated with success across the two time periods. One possible explanation is sampling variability: sample sizes for the two analyses varied based on follow-up time. Limitations of this study relate to its retrospective nature, which precluded systematic collection of many potential correlates of transition and/

or engagement in care. And, although ALWH who wished to transfer their care to a different facility would theoretically require a transfer referral from the initial treatment center, we cannot rule out the possibility that some ALWH who were lost from care were in fact receiving treatment elsewhere. The data on absence of viral load testing are difficult to interpret as this may be due to health systems factors (e.g., lack of reagents, viral load not ordered) in addition to patient-level factors. To account for this possibility, we defined successful transition based on the more conservative assumption that ALWH should have had at least one viral load during a one-year period. Additionally, although this work was conducted at a single public sector facility, the study site was a major provider of ART in Lima and is generally thought to be representative of the public sector treatment experience in tertiary care facilities. Thus, our results are likely generalizable to other urban centers in Peru and perhaps beyond. Finally, our definition of retention was based on that used by the Peru National HIV Program, and recent work has shown that retention rates can vary greatly depending on the definition used [47].

In conclusion, we found low rates of sustained retention with viral load suppression within the first two years of ART among adolescents and young adults newly diagnosed with HIV. The development and evaluation of differentiated interventions to

**Table 3**Univariable analyses of baseline predictors of successful transition at 12 and 24 months among adolescents and young adults recently diagnosed with HIV in Lima, Peru

Variable	12 months (N = 177) <sup>a</sup>			24 months (N = 83) <sup>a</sup>		
	n <sup>b</sup>	Risk ratio (95% CI)	P value	n <sup>b</sup>	Risk ratio (95% CI)	P value
Age at transition (years)		0.97 (0.86, 1.10)	.64	_	1.01 (0.83,1.24)	.90
Calendar year of transition	-	1.00 (0.84, 1.18)	.98	-	1.10 (0.76, 1.91)	.44
Male	160	1.08 (0.59, 1.96)	.80	77	0.70 (0.30, 1.66)	.42
Activity						
Neither works nor studies	24	Reference		13	Reference	
Works and studies	21	0.46 (0.22, 0.96)	.04	8	0.81 (0.19, 3.50)	.78
Works	68	0.73 (0.49, 1.09)	.13	36	1.35 (0.55, 3.36)	.51
Studies	58	0.69 (0.45, 1.06)	.09	23	1.13 (0.42, 3.06)	.81
Living alone	23	0.77 (0.43, 1.38)	.37	9	1.26 (0.57, 2.81)	.56
No support agent <sup>c</sup>	37	1.14 (0.77, 1.67)	.52	9	0.91 (0.34, 2.43)	.86
Mental health diagnosis	45	1.47 (1.06, 2.04)	.02	33	0.76 (0.41, 1.41)	.38
Number of known living parents	_	1.24 (0.96, 1.61)	.10	_	2.40 (1.23, 4.66)	.01
No social risk factors	28	1.37 (0.94, 2.00)	.096	14	2.11 (1.24, 3.60)	.01
MSM	145	0.93 (0.61, 1.40)	.72	68	0.62 (0.34, 1.09)	.096
Venezuelan nationality	13	1.24 (0.73, 2.12)	.42	1	_ ` ` ` `	_
Baseline CD4 cell count						
< 50	5	Reference		4	Reference	
51-200	19	1.58 (0.24, 10.34)	.63	5	1.60 (0.21, 12.07)	.65
201-500	91	2.31 (0.39, 13.58)	.36	49	1.47 (0.26, 8.43)	.67
> 500	56	2.59 (0.44, 15.39)	.29	25	1.44 (0.24, 8.60)	.69

 $CD4 = clusters \ of \ differentiation \ 4; \ CI = confidence \ interval; \ MSM = men \ who \ have \ sex \ with \ men.$ 

<sup>\*</sup> An adolescent was considered at risk if they were eligible to have completed the corresponding duration of follow-up, based on the antiretroviral therapy initiation date and date of chart review.

<sup>&</sup>lt;sup>a</sup> Seven and two individuals who transferred out were excluded from 12- and 24-month analyses, respectively.

<sup>&</sup>lt;sup>b</sup> Provided for binary and categorical variables; not provided for continuous variables.

<sup>&</sup>lt;sup>c</sup> Missing indicator method used to account for missing data in this variable.




Figure 1. Multivariable analyses of baseline predictors of successful transition at 12 and 24 months among adolescents and young adults recently diagnosed with HIV in Lima, Peru: (A) Activity (reference group is neither works nor studies); (B) Number of known living parents; (C) No note of known social risk factors; (D) MSM; (E) Any note of mental health diagnosis. Note: Factors significantly correlated with successful transition (P < .20) at any time point were included in the multivariate analysis.

support this population, particularly those aiming to address gaps in social support and facilitate the provision of adolescentfriendly care, are of utmost priority.

Author Contributions: Conceptualization: M.F., S.S., C.B., and L.L. Data collection: A.R., L.S., R.E., and M.W. Data curation: C.R. and A.L. Methodology: M.F. Analysis: M.N., C.R., M.F., C.C., and J.G. Supervision: M.F., E.M., M.W., and L.L. Writing—original draft: M.N. and M.F. Writing—review and editing: All.

#### **Supplementary Data**

Supplementary data related to this article can be found at http://doi.org/10.1016/j.jadohealth.2023.08.041.

#### **Funding Sources**

This research was entirely supported by the National Institutes of Allergy and Infectious Diseases of the United States National Institutes of Health under award number R21Al143365. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

#### References

- [1] Straub DM, Tanner AE. Health-care transition from adolescent to adult services for young people with HIV. Lancet Child Adolesc Health 2018;2: 214–22
- [2] Hussen SA, Chakraborty R, Knezevic A, et al. Transitioning young adults from paediatric to adult care and the HIV care continuum in Atlanta, Georgia, USA: A retrospective cohort study. J Int AIDS Soc 2017;20:21848.
- [3] Abadía-Barrero CE, Castro A. Experiences of stigma and access to HAART in children and adolescents living with HIV/AIDS in Brazil. Soc Sci Med 2006; 62:1219–28.
- [4] Steinberg L. Commentary: A behavioral scientist looks at the science of adolescent brain development, Brain Cogn 2010:72:160.
- [5] Tepper V, Zaner S, Ryscavage P. HIV healthcare transition outcomes among youth in North America and Europe: A review. J Int AIDS Soc 2017;20: 21490.
- [6] Kakkar F, Van der Linden D, Valois S, et al. Health outcomes and the transition experience of HIV-infected adolescents after transfer to adult care in Québec, Canada. BMC Pediatr 2016;16:109.
- [7] Weijsenfeld AM, Smit C, Cohen S, et al. Virological and social outcomes of HIV-infected adolescents and young adults in The Netherlands before and after transition to adult care. Clin Infect Dis 2016;63:1105–12.
- [8] Lam PK, Fidler S, Foster C. A review of transition experiences in perinatally and behaviourally acquired HIV-1 infection; same, same but different? J Int AIDS Soc 2017;20:21506.
- [9] Centro Nacional de Epidemiología; Prevención y Control de Enfermedades. Situación Epidemiológica Del VIH-Sida En El Perú. Boletín Mensual. 2018. Available at: https://www.dge.gob.pe/portal/docs/vigilancia/vih/Boletin\_2018/diciembre.pdf.
- [10] Cáceres CF, Aggleton P, Galea JT. Sexual diversity, social inclusion and HIV/ AIDS. AIDS Lond Engl 2008;22:S45—55.
- [11] Committee On Adolescence. Office-based care for lesbian, gay, bisexual, transgender, and questioning youth. Pediatrics 2013;132:198–203.
- [12] Brown LK, Whiteley L, Harper GW, et al. ATN 086 Protocol Team for the adolescent medicine Trials network for HIV/AIDS interventions. Psychological symptoms among 2032 youth living with HIV: A multisite study. AIDS Patient Care STDS 2015;29:212–9.
- [13] Conner LC, Wiener J, Lewis JV, et al. Prevalence and predictors of Drug Use among adolescents with HIV infection acquired perinatally or later in life. AIDS Behav 2013;17:976–86.
- [14] Lewis JV, Abramowitz S, Koenig LJ, et al. Negative life events and depression in adolescents with HIV: A stress and coping analysis. AIDS Care 2015; 27:1265—74.
- [15] Herrick A, Stall R, Egan J, et al. Pathways towards risk: Syndemic conditions mediate the effect of adversity on HIV risk behaviors among young men who have sex with men (YMSM). J Urban Health Bull N Y Acad Med 2014; 91:969–82
- [16] Chandwani S, Koenig LJ, Sill AM, et al. Predictors of antiretroviral medication adherence among a diverse cohort of adolescents with HIV. J Adolesc Health 2012;51:242–51.

- [17] Valenzuela JM, Buchanan CL, Radcliffe J, et al. Transition to adult services among behaviorally infected adolescents with HIV—a Qualitative study. J Pediatr Psychol 2011;36:134–40.
- [18] Fields EL, Bogart LM, Thurston IB, et al. Qualitative comparison of barriers to antiretroviral medication adherence among perinatally and behaviorally HIV-infected youth. Qual Health Res 2017;27:1177—89.
- [19] Koenig LJ, Pals SL, Chandwani S, et al. Sexual Transmission risk behavior of adolescents with HIV acquired perinatally or through Risky behaviors. JAIDS J Acquir Immune Defic Syndr 2010;55:380–90.
- [20] Centro Nacional de Epidemiología; Prevención y Control de Enfermedades. Situación Epidemiológica Del VIH-Sida En El Perú. 2020. Available at: https://www.dge.gob.pe/portal/docs/vigilancia/vih/Boletin\_2020/febrero.pdf.
- [21] UNAIDS. Peru country fact Sheet 2019. 2020. Available at: https://www.unaids.org/en/regionscountries/countries/peru.
- [22] Centro Nacional de Epidemiología; Prevención y Control de Enfermedades. Situación Epidemiológica Del VIH-Sida En El Perú. 2021. Available at: https://www.dge.gob.pe/portal/docs/vigilancia/vih/Boletin\_2021/febrero.pdf.
- [23] Santisteban AS. Diagnóstico Rápido: Situación de Los Migrantes Venezolanos Con VIH En El Perú. ONUSIDA. 2019. Available at: http://onusidalac.org/1/images/2018/diagnostico-rapido-migrantes-con-vih-peru.pdf.
- [24] Huerta-Vera GS, Amarista MA, Mejía FA, et al. Clinical situation of Venezuelan migrants living with HIV in a hospital in Lima, Peru. Int J STD AIDS 2021;32:1157–64.
- [25] UNAIDS. Social and Economic Integration of Venezuelan Migrants. 2022. Available at: https://www.usaid.gov/news-information/fact-sheets/social-and-economic-integration-venezuelan-migrants. Accessed February 9, 2022.
- [26] Ministerio de Salud. Norma Técnica de Salud de Atención Integral Del Adulto Con Infección por El Virus de La Inmunodeficiencia Humana. Lima, Peru: VIH: 2014
- [27] Resolución Ministerial. 2020. Available at: https://cdn.www.gob.pe/uploads/document/file/1482085/Resoluci%C3%B3n%20Ministerial%20N%C2%B01024-2020-MINSA.PDF.
- [28] Ehrenkranz P, Rosen S, Boulle A, et al. The revolving door of HIV care: Revising the service delivery cascade to achieve the UNAIDS 95-95-95 goals. PLoS Med 2021;18:e1003651.
- [29] Bailey H, Cruz MLS, Songtaweesin WN, Puthanakit T. Adolescents with HIV and transition to adult care in the Caribbean, Central America and South America, Eastern Europe and Asia and Pacific regions. J Int AIDS Soc 2017; 20:21475.
- [30] Nassau T, Loabile B, Dowshen N, et al. Factors and outcomes associated with viral suppression Trajectory group Membership among youth transitioning from pediatric to adult HIV care. J Adolesc Health 2022;71: 737–43.
- [31] Sohn AH, Singtoroj T, Chokephaibulkit K, et al. Long-term post-transition outcomes of adolescents and young adults living with perinatally and Non-perinatally acquired HIV in Southeast Asia. J Adolesc Health 2023;72: 471–6
- [32] Rodriguez CA, Kolevic L, Ramos A, et al. Lifetime Changes in CD4 T-cell count, viral load suppression and adherence among adolescents living with HIV in urban Peru. Pediatr Infect Dis J 2020;39:54—6.
- [33] Wong VJ, Murray KR, Phelps BR, et al. Adolescents, young people, and the 90–90–90 goals: A call to improve HIV testing and linkage to treatment. AIDS Lond Engl 2017;31:S191–4.
- [34] Philbin M, Tanner A, Chambers B, et al. Transitioning HIV-infected adolescents to adult care at 14 clinics across the United States: Using adolescent and adult providers' insights to create multi-level solutions to address transition barriers. AIDS Care 2017;29:1–8.
- [35] Rooks-Peck CR, Adegbite AH, Wichser ME, et al. Mental health and retention in HIV care: A systematic review and Meta-analysis. Health Psychol 2018;37:574–85.
- [36] Enane LA, Apondi E, Omollo M, et al. "I just keep quiet about it and act as if everything is alright" - the cascade from trauma to disengagement among adolescents living with HIV in western Kenya. J Int AIDS Soc 2021;24: e25695.
- [37] Krumme AA, Kaigamba F, Binagwaho A, et al. Depression, adherence and attrition from care in HIV-infected adults receiving antiretroviral therapy. J Epidemiol Community Health 2015;69:284—9.
- [38] Haas AD, Ruffieux Y, van den Heuvel LL, et al. Excess mortality associated with mental illness in people living with HIV in Cape Town, South Africa: A cohort study using linked electronic health records. Lancet Glob Health 2020;8:e1326—34.
- [39] Haas AD, Technau KG, Pahad S, et al. Mental health, substance use and viral suppression in adolescents receiving ART at a paediatric HIV clinic in South Africa. J Int AIDS Soc 2020;23:e25644.
- [40] Ritchwood TD, Malo V, Jones C, et al. Healthcare retention and clinical outcomes among adolescents living with HIV after transition from pediatric to adult care: A systematic review. BMC Publ Health 2020;20:1195.
- [41] Vargas V, Wong M, Rodriguez CA, et al. Community-based Accompaniment for adolescents transitioning to adult HIV care in urban Peru: A pilot study |

- medRxiv. Available at: https://www.medrxiv.org/content/10.1101/2021. 08.25.21261815v1.full. Accessed February 3, 2022.
- [42] Ruria EC, Masaba R, Kose J, et al. Optimizing linkage to care and initiation and retention on treatment of adolescents with newly diagnosed HIV infection. AIDS Lond Engl 2017;31:S253-60.
- [43] Zanoni BC, Sibaya T, Cairns C, et al. Higher retention and viral suppression with adolescent-focused HIV clinic in South Africa. PLoS One 2017;12: e0190260.
- [44] Tanner AE, Philbin MM, Ma A, et al. Adolescent to adult HIV health care transition from the perspective of adult providers in the United States. J Adolesc Health 2017;61:434–9.
- [45] Mbalinda SN, Bakeera-Kitaka S, Lusota DA, et al. Transition to adult care: Exploring factors associated with transition readiness among adolescents and young people in adolescent ART clinics in Uganda. PLoS One 2021;16: e0249971.
- [46] Galea JT, Wong M, Ninesling B, et al. Patient and provider perceptions of a community-based accompaniment intervention for adolescents transitioning to adult HIV care in urban Peru: A qualitative analysis. J Int AIDS Soc 2022;25:e26019.
- [47] Sayegh CS, Wood SM, Belzer M, Dowshen NL. Comparing different Measures of retention in care among a cohort of adolescents and young adults living with behaviorally-acquired HIV. AIDS Behav 2020;24:304–10.